Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Symbool: 002693.SZ
SHZ
5.69
CNYMarktprijs vandaag
-39.5632
Koers/Winst Verhouding
2.2749
Koers/Winst Groei Verhouding
2.36B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 31.9 | 146 | 77 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 28.5 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 16.4 | 41 | 33.1 | |||||||||||||||
balance-sheet.row.inventory | 0 | 74.3 | 65.4 | 55.2 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.2 | 0 | 0.1 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 135.2 | 252.4 | 165.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 457.6 | 471.8 | 504.7 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 10 | 8.8 | 17.3 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 1.5 | 1 | 1 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 27.1 | 12.2 | 9.1 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 668 | 658.6 | 689.1 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 17.1 | 15.5 | 17.2 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 10.1 | 205.3 | 0.3 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 3.7 | 12.8 | 7.2 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 135 | 0 | 167 | |||||||||||||||
Deferred Revenue Non Current | 0 | 8 | 7.6 | 8.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 2 | 73.6 | 1.8 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 145.7 | 10.7 | 179.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 285.6 | 330.1 | 287.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 34.4 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 416.7 | 414.7 | 412 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | -347 | -296.2 | -305.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -0.4 | 87.2 | 82.2 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 367.6 | 307.9 | 292.9 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 471.5 | 513.5 | 481.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 46.2 | 67.4 | 84.9 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 517.6 | 580.9 | 566.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 10 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 145.1 | 205.3 | 167.3 | |||||||||||||||
balance-sheet.row.net-debt | 0 | 141.7 | 193.1 | 145.6 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | 0 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | 0 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 0 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | 0 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | 0 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 0 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | 0 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | 0 | -7.8 | -8.1 | -62.1 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 235.9 | 274.8 | 320.3 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 74.9 | 88.3 | 81.4 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 161.1 | 186.5 | 238.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 183.4 | 215.8 | 282.7 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 258.3 | 304.1 | 364.1 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0.1 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 52.7 | 57.5 | 54.3 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | -73.2 | -24.5 | -42.3 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | -73 | -8.9 | -40.4 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | -1 | -0.4 | 0.4 | |||||||||||||||
income-statement-row.row.net-income | 0 | -50.7 | -8.5 | -40.8 |
Vaak gestelde vragen
Wat is Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) totale activa?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) totale activa is 803248121.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.654.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.324.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.443.
Wat is Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) nettowinst (netto-inkomen)?
De nettowinst is -50741578.370.
Wat is de totale schuld van het bedrijf?
De totale schuld is 145050750.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 183423820.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.